<DOC>
	<DOCNO>NCT01021579</DOCNO>
	<brief_summary>Polycystic ovary syndrome ( PCOS ) common endocrinopathy affect 6.5 % -6.7 % woman reproductive age , commonly associate obesity , menstrual irregularity , insulin resistance ( IR ) , infertility , clinical hyperandrogenism and/or hyperandrogenemia ( 1,2 ) . PCOS also associate increase risk abnormal lipoproteins hypertension , well cardiovascular cerebrovascular morbidity ( 3 ) . The lipid lipoprotein profile androgenized woman poly cystic ovary similar make pattern high level cholesterol , low-density lipoprotein ( LDL ) , low level high-density lipoprotein ( HDL ) , abnormal pattern independent body weight ( 4 ) . Insulin resistance associate reproductive abnormality woman PCOS . Improving insulin sensitivity lifestyle pharmacological intervention ameliorate abnormality . Insulin resistance woman PCOS common ( 50 % ) , obese nonobese woman ( 5 ) , disordered insulin action precedes increase androgen . Treatment PCOS subject typically include , implementation lifestyle change especially weight loss adjuvant pharmaceutical intervention include oral contraceptive , anti-androgen therapy insulin-lowering drug ( , metformin ) ( 6 ) . Metformin biguanide use extensively type 2 diabetes . It inhibit hepatic glucose production increase peripheral insulin sensitivity , dose cause hypoglycemia . Several study show increase insulin sensitivity pregnancy rate accompany decrease insulin androgen level PCOS patient take metformin ( 7 ) . The 3-hydroxy-3-methylglutaryl coenzyme A ( HMG-COA ) reductase inhibitor ( statin ) rate-limiting step cholesterol biosynthesis , inhibition enzyme decrease cholesterol synthesis compensatory increase expression LDL receptor liver . Statins reduce plasma triglyceride dose-dependent fashion also modest HDL-raising effect dose-dependent ( 8,9 ) . Furthermore , statins pose cardio-protective property , include antioxidant anti-inflammatory action ( 10,11 ) . Some study report simvastatin decrease serum androgen level woman PCOS ( 12,13 ) inhibit proliferation steroidogenesis ovarian theca-interstitial cell ( 14 ) . According previous finding , hypothesize combination therapy simvastatin metformin result lower androgen level cardiovascular risk factor woman PCOS .</brief_summary>
	<brief_title>Effects Metformin Plus Simvastatin Polycystic Ovarian Syndrome ( PCOS ) : A Prospective , Randomized , Double-Blind , Placebo-Controlled Study</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Polycystic Ovary Syndrome</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<criteria>All patient least two three follow criterion : I ) chronic anovulation , II ) clinical and/or biochemical evidence androgen excess III ) polycysticappearing ovary transvaginal ultrasound . Patients Cushing 's syndrome , hyperprolactinemia , diabetes mellitus ( DM ) , thyroid disease , adrenal hyperplasia androgensecreting tumor endocrinopathies , exclude study . Patients adrenal hyperplasia exclude ACTHstimulated 17hydroxyprogesterone level less 10 ng/ml ( 15 ) , ACTHstimulated 11deoxycortisol level less 21 ng/ml [ 3fold 95th percentile ( 16 ) historical control group 60 healthy woman control ] . Those subject kidney liver disease smoker breast cancer also exclude study . None participant receive oral contraceptive ( OCPs ) , steroid hormone medication interfere lipid metabolism , ovarian pituitary hypothalamic function , insulin sensitivity last 3 month study .</criteria>
	<gender>Female</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>Polycystic ovary syndrome</keyword>
	<keyword>Metformin</keyword>
	<keyword>Simvastatin</keyword>
</DOC>